Krsnaa Diagnost. Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹240 Cr +31.1% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
KD

Krsnaa Diagnost.

Q2 FY26

Krsnaa Diagnostics Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹183Cr
+2.2% YoY
+4% QoQ
Net profit
₹23Cr
+4.5% YoY
+15% QoQ
Margin
32%
+3 pp YoY
+3 pp QoQ
Price₹562
Market cap₹1.9K Cr
P/E19.2

The short version

Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone. Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs. 60 crore and PAT increasing 22% YoY to Rs. 24 crore in Q2 FY '26.

From Krsnaa Diagnost.'s Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone.
  • Revenue growth expected in higher teens percentage over next couple of years.
  • Q4 FY '26 expected to reach Rs. 100 crore quarterly run rate in retail business due to fast expansion.
  • Volume growth strategies include introducing wellness packages and advanced test menus, supporting sustainable growth in both PPP and retail channels.
  • Rajasthan PPP contract expected to kick in FY '27 onwards, providing significant revenue uptick.
  • Overall revenue expected to grow robustly with retail contributing 8-10% in FY '26, accelerating to 15-20% in next financial year.

2 more points from Krsnaa Diagnost.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • For the current fiscal year, excluding Rajasthan, Krsnaa Diagnostics has planned CAPEX of Rs. 150 crores to Rs. 170 crores.
  • Rs. 80 crores of CAPEX has already been incurred: Rs. 50 crores capitalized and Rs. 30 crores in work-in-progress, mainly for radiology equipment.
  • Maharashtra MRI centers are in the final stages of implementation, with assets procured on deferred payments (only 20-25% paid initially).
  • Rajasthan expansion involves establishing around 10 labs by December and 25 labs plus 500 centers by Q4.
  • Deferred payment and lease models for equipment are being leveraged for capital efficiency.

2 more points from Krsnaa Diagnost.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Maharashtra: 15 MRI centers are under implementation; 10 are near completion and awaiting inauguration.
  • Rajasthan: Establishing 10 labs soon; target of 25 labs and 500 centers by December, with remaining centers completed in Q4.
  • Pipeline: Several tenders are in various stages across different states; details kept confidential due to competitive nature.
  • Attributed to tender timing and government processes, not reduced tender pipeline.

2 more points from Krsnaa Diagnost.'s call on order book

Create a free account to keep reading this call

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Krsnaa Diagnost. Q2 FY26 results — key figures

Krsnaa Diagnost. Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue183179+2.2%176+4%
Operating profit (EBITDA)5852+11.5%50+16%
Operating margin32%29%+3 pp29%+3 pp
Profit before tax3128+10.7%26+19.2%
Net profit (PAT)2322+4.5%20+15%
EPS (₹)7.166.80+5.3%6.03+18.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Maitreya Medicare (Q2 FY26)

    23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.

  • Metropolis Healt (Q2 FY26)

    Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…

  • 3B Blackbio (Q2 FY26)

    Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…

  • Unihealth Hosp (Q2 FY26)

    Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Krsnaa Diagnost. Q2 FY26 results?

Retail segment aims to contribute 40-50% of total sales in the next five years, targeting Rs. 600-1,000 crores sales from retail alone. Krsnaa Diagnostics expects robust earnings growth, with EBITDA up 18% YoY to Rs. 60 crore and PAT increasing 22% YoY to Rs. 24 crore in Q2 FY '26.

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

For the current fiscal year, excluding Rajasthan, Krsnaa Diagnostics has planned CAPEX of Rs. 150 crores to Rs. 170 crores.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.